S-Nitrosylation of CRTC1 in Alzheimer’s disease impairs CREB-dependent gene expression induced by neuronal activity

X Xu Zhang R Roman Vlkolinsky C Chongyang Wu (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) N Nima Dolatabadi (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) H Henry Scott (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) O Olga Prikhodko (Department of Neurosciences, University of California San Diego, School of Medicine) A Andrew Zhang (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) M Mayra Blanco (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) N Nhi Lang (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) J Juan Piña-Crespo (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) T Tomohiro Nakamura (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute) M Marisa Roberto S Stuart A. Lipton (Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute)

Abstract

cAMP response element-binding protein (CREB)-regulated transcription coactivator 1 (CRTC1) plays an important role in synaptic plasticity, learning, and long-term memory formation through the regulation of neuronal activity-dependent gene expression, and CRTC1 dysregulation is implicated in Alzheimer’s disease (AD). Here, we show that increased S-nitrosylation of CRTC1 (forming SNO-CRTC1), as seen in cell-based, animal-based, and human-induced pluripotent stem cell (hiPSC)-derived cerebrocortical neuron-based AD models, disrupts its binding with CREB and diminishes the activity-dependent gene expression mediated by the CRTC1/CREB pathway. We identified Cys216 of CRTC1 as the primary target of S-nitrosylation by nitric oxide (NO)-related species. Using CRISPR/Cas9 techniques, we mutated Cys216 to Ala in hiPSC-derived cerebrocortical neurons bearing one allele of the APP Swe mutation (AD-hiPSC neurons). Introduction of this nonnitrosylatable CRTC1 mutant rescued defects in AD-hiPSC neurons, including decreased neurite length and increased neuronal cell death. Additionally, expression of nonnitrosylatable CRTC1 in vivo in the hippocampus rescued synaptic plasticity in the form of long-term potentiation in 5XFAD mice. Taken together, these results demonstrate that formation of SNO-CRTC1 contributes to the pathogenesis of AD by attenuating the neuronal activity-dependent CREB transcriptional pathway, and suggests a therapeutic target for AD.

Article Details

Volume / Issue Vol. 122, Issue 9
Published March 04, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (13)

X

Xu Zhang

R

Roman Vlkolinsky

C

Chongyang Wu

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

N

Nima Dolatabadi

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

H

Henry Scott

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

O

Olga Prikhodko

Department of Neurosciences, University of California San Diego, School of Medicine

A

Andrew Zhang

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

M

Mayra Blanco

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

N

Nhi Lang

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

J

Juan Piña-Crespo

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

T

Tomohiro Nakamura

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute

M

Marisa Roberto

S

Stuart A. Lipton

Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute